COVID-19: Resources
COVID-19: Moving Forward Together
02/07/2020 - 13:24
Tocilizumab in COVID-19 - Which Clinical Benefits?
11/06/2020 - 15:04
Lessons for Internists about the Pandemic
11/06/2020 - 11:16Latest News
IMAGINE the future - a voice of young internists - JAMA
We are pleased to inform you that EFIM IMAGINE Working Group published their paper "IMAGINE the future - a voice of young internists" in JAMA under the title "Sex, Gender, and Precision Medicine". Article can be accessed via JAMA website
here: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2766914?resultClick=1.
Tocilizumab in COVID-19 - Which Clinical Benefits?
Tocilizumab is a recombinant humanized monoclonal IL-6 receptor antibody indicated for the treatment of severe rheumatoid arthritis and other inflammatory disorders.Following clinical observation from China, a series of Italian studies have been carried out to evaluate the off-label use of tocilizumab in COVID-19 patients.
The European Journal of Internal Medicine (EJIM) has recently accepted for publication three articles on the off-label use of tocilizumab in patients with severe COVID-19.
Corona virus information centre
Visit the Information Center available through our publisher Elsevier, to find the most relevant research on the Novel Coronavirus (COVID-19), freely available here.
